We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
IQV has a decent earnings surprise history, having surpassed the Zacks Consensus Estimate in the trailing four quarters, the average surprise being 1.7%.
IQVIA Holdings Inc. Price, Consensus and EPS Surprise
The Zacks Consensus Estimate for revenues is pegged at $3.8 billion, increasing marginally on a year-over-year basis.
Research and Development Solutions (R&DS) revenues are expected to be $2.1 billion, hinting at a 1.6% rise from the year-ago reported figure. New partnerships and the launch of the latest treatments are expected to have fueled this segment’s revenue growth.
Our estimate for revenues from Technology and Analytics Solutions (TAS) is pegged at $1.5 billion, indicating a 1% rise on a year-over-year basis. Robust demand for integrated solutions that combine information, analytics and services is likely to have improved the segment’s revenues.
Our estimate for Contract sales and Medical solutions’ revenues is pegged at $192 million, implying 1.8% growth from the year-ago quarter’s actual.
The consensus estimate for earnings per share is pegged at $2.63, suggesting 3.5% year-over-year growth.
Our estimate for the first quarter’s adjusted EBITDA is pegged at $886.6 million, suggesting 2.9% year-over-year growth. A strong top line and price discipline are expected to have driven the bottom line.
What Our Model Says About IQV
Our proven model does not conclusively predict an earnings beat for IQVIA this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that is not the case here. You can uncover the best stocks before they are reported with our Earnings ESP Filter.
IQV has an Earnings ESP of -0.27% and a Zacks Rank of 4 (Sell) at present.
Stocks to Consider
Here are a few stocks from the broader Medical sector, which, according to our model, have the right combination of elements to beat on earnings this time around.
Novo Nordisk (NVO - Free Report) : The Zacks Consensus Estimate for the company’s first-quarter 2025 revenues is pegged at $11.3 billion, suggesting growth of 19.1% from the year-ago quarter’s actual. For earnings, the consensus mark is pegged at 91 cents per share, indicating a 9.6% year-over-year rise. NVO beat the consensus estimate in the past two of the four quarters and missed in the remaining two, with an average earnings surprise of 1.9%.
It is scheduled to declare its first-quarter 2025 results on May 7. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)
Pacira BioSciences, Inc. (PCRX - Free Report) : The Zacks Consensus Estimate for the company’s first-quarter 2025 revenues is pegged at $174.9 million, indicating year-over-year growth of 4.7%. For earnings, the consensus mark is pegged at 57 cents per share, suggesting an 8.1% decline from the year-ago quarter’s reported figure. The company beat the consensus estimate in three of the past four quarters and missed once, with an average surprise of 8.6%.
PCRX carries an Earnings ESP of +34.51% and a Zacks Rank of 3 at present. The company is scheduled to declare its first-quarter 2025 results on May 8.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
IQVIA Gears Up to Report Q1 Earnings: What's in Store for the Stock?
IQVIA Holdings Inc. (IQV - Free Report) will release its first-quarter 2025 results on May 6, before market open.
IQV has a decent earnings surprise history, having surpassed the Zacks Consensus Estimate in the trailing four quarters, the average surprise being 1.7%.
IQVIA Holdings Inc. Price, Consensus and EPS Surprise
IQVIA Holdings Inc. price-consensus-eps-surprise-chart | IQVIA Holdings Inc. Quote
IQVIA’s Q1 Expectations
The Zacks Consensus Estimate for revenues is pegged at $3.8 billion, increasing marginally on a year-over-year basis.
Research and Development Solutions (R&DS) revenues are expected to be $2.1 billion, hinting at a 1.6% rise from the year-ago reported figure. New partnerships and the launch of the latest treatments are expected to have fueled this segment’s revenue growth.
Our estimate for revenues from Technology and Analytics Solutions (TAS) is pegged at $1.5 billion, indicating a 1% rise on a year-over-year basis. Robust demand for integrated solutions that combine information, analytics and services is likely to have improved the segment’s revenues.
Our estimate for Contract sales and Medical solutions’ revenues is pegged at $192 million, implying 1.8% growth from the year-ago quarter’s actual.
The consensus estimate for earnings per share is pegged at $2.63, suggesting 3.5% year-over-year growth.
Our estimate for the first quarter’s adjusted EBITDA is pegged at $886.6 million, suggesting 2.9% year-over-year growth. A strong top line and price discipline are expected to have driven the bottom line.
What Our Model Says About IQV
Our proven model does not conclusively predict an earnings beat for IQVIA this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that is not the case here. You can uncover the best stocks before they are reported with our Earnings ESP Filter.
IQV has an Earnings ESP of -0.27% and a Zacks Rank of 4 (Sell) at present.
Stocks to Consider
Here are a few stocks from the broader Medical sector, which, according to our model, have the right combination of elements to beat on earnings this time around.
Novo Nordisk (NVO - Free Report) : The Zacks Consensus Estimate for the company’s first-quarter 2025 revenues is pegged at $11.3 billion, suggesting growth of 19.1% from the year-ago quarter’s actual. For earnings, the consensus mark is pegged at 91 cents per share, indicating a 9.6% year-over-year rise. NVO beat the consensus estimate in the past two of the four quarters and missed in the remaining two, with an average earnings surprise of 1.9%.
NVO has an Earnings ESP of +0.28% and a Zacks Rank of 3 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
It is scheduled to declare its first-quarter 2025 results on May 7. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)
Pacira BioSciences, Inc. (PCRX - Free Report) : The Zacks Consensus Estimate for the company’s first-quarter 2025 revenues is pegged at $174.9 million, indicating year-over-year growth of 4.7%. For earnings, the consensus mark is pegged at 57 cents per share, suggesting an 8.1% decline from the year-ago quarter’s reported figure. The company beat the consensus estimate in three of the past four quarters and missed once, with an average surprise of 8.6%.
PCRX carries an Earnings ESP of +34.51% and a Zacks Rank of 3 at present. The company is scheduled to declare its first-quarter 2025 results on May 8.